Treace Medical Concepts, Inc. TMCI
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -3.86% | -24.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.86% | -24.51% | |||
| Cost of Revenue | -0.22% | -19.20% | |||
| Gross Profit | -4.81% | -25.78% | |||
| SG&A Expenses | -7.53% | -3.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.26% | -5.96% | |||
| Operating Income | 12.87% | -189.89% | |||
| Income Before Tax | 11.63% | -91.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.63% | -91.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.63% | -91.20% | |||
| EBIT | 12.87% | -189.89% | |||
| EBITDA | 19.66% | -295.43% | |||
| EPS Basic | 12.26% | -89.06% | |||
| Normalized Basic EPS | 12.26% | -166.56% | |||
| EPS Diluted | 12.26% | -89.06% | |||
| Normalized Diluted EPS | 12.26% | -166.56% | |||
| Average Basic Shares Outstanding | 0.71% | 1.15% | |||
| Average Diluted Shares Outstanding | 0.71% | 1.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||